Stopping Oxytocin During Active Labour: Effects on Caesarean Rates and Safety
When clinicians administer intravenous oxytocin to induce or augment labour, deciding whether to stop or continue the infusion once active labour begins yields little to no difference in overall caesarean section rates, according to a comprehensive systematic review updated in November 2025. Evaluating data from nine international clinical trials encompassing 4,814 women across hospitals in Denmark, France, India, Iran, Israel, Thailand, Turkey, and the USA, researchers assessed the physiological impacts of discontinuing the uterotonic agent at the four-centimetre cervical dilation mark versus maintaining the drip until birth.
Cochrane Review Questions Oxytocin Infusion Protocols in Active Labour
Key Clinical Takeaways:
- Stopping oxytocin at the onset of active labour shows little to no difference in caesarean or instrumental delivery rates compared to continuous infusion.
- Discontinuation may reduce the incidence of uterine tachysystole or hyperstimulation, preventing excessive uterine contractions that stress the fetus.
- Active labour duration may extend by approximately 35 minutes when oxytocin is stopped, though this specific finding carries high statistical uncertainty.
The Physiology of Parturition and Hyperstimulation Risks
The core clinical dilemma centres on the natural physiology of parturition. Near term, defined as gestation after 37 weeks, artificial oxytocin stimulates smooth muscle contractions in the womb. Once a pregnant patient reaches active labour—marked by regular contractions and at least four centimetres of cervical dilation—endogenous oxytocin production typically sustains labour progression. Maintaining exogenous oxytocin delivery past this threshold risks hyperstimulation, which can cause stress to the baby and potentially increase the likelihood of a woman needing to have a caesarean section.
Weighing Delivery Rates Against Uterine Safety
To evaluate these outcomes, investigators analysed nine trials investigating singleton term pregnancies where oxytocin was utilised for induction or augmentation. The synthesized evidence indicates that stopping oxytocin during the active phase makes little or no difference to the frequency of caesarean births across eight studies involving 4,710 women. Similarly, analysis of five trials with 3,776 participants revealed no significant variance in instrumental births. However, data from three trials involving 1,371 women demonstrated that discontinuing the infusion may lower the risk of uterine hyperstimulation.
Neonatal Outcomes and Labour Duration
Neonatal safety parameters remained consistent across both clinical approaches. Five trials tracking 2,096 infants found no clear difference in Apgar scores between the continuation and discontinuation groups. Testing the blood from the umbilical cord after birth across six studies comprising 4,086 newborns showed no discernible disparity in signs of reduced oxygen supply to the baby before birth. Furthermore, admission to the neonatal unit exhibited probably little to no difference across seven trials covering 4,606 infants. While labour duration lengthened by an average of 35 minutes upon oxytocin cessation across eight studies with 4,141 participants, authors noted substantial uncertainty surrounding this metric.
Individualized Care and Institutional Protocols
Clinical decision-making regarding oxytocin management requires individualized patient assessment. Healthcare providers must evaluate the immediate clinical context, including labour progress, contractions, current condition of woman and baby, and the monitoring that is available.
Study limitations identified in the review include unmasked participants and variations in trial definitions for active labour, uterine tachysystole, and hyperstimulation. Expectant mothers and clinical teams should review labor management preferences alongside available monitoring when determining the optimal infusion strategy.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.